

Appl. No. 10/044,645
Amdt. dated June 16, 2003
Reply to Office Action of December 17, 2002

This listing of the claims will replace all prior versions, and listing, of claims in the application.

Listing of Claims:

Claim 1 (currently amended): A composition comprising *Serenoa repens* or an extract thereof and a sympathomimetic agent, wherein the sympathomimetic agent is ~~selected from the group consisting of synephrine and phenylpropanolamine~~, wherein the composition is suitable for oral administration.

Claim 2 (original): The composition of claim 1, wherein the *Serenoa repens* or extract thereof has anti-adrenergic activity.

Claim 3 (original): The composition of claim 2, wherein the anti-adrenergic activity is inhibition of agonist binding to the alpha-adrenergic receptor.

B¹
Claim 4 (original): The composition of claim 1, wherein the composition is in pharmaceutically acceptable form.

Claims 5-8 (previously cancelled)

Claim 9 (currently amended): A composition comprising *Serenoa repens* or an extract thereof and a sympathomimetic agent, wherein the sympathomimetic agent is ^{an extract of} *Citrus aurantium* or other natural source of synephrine containing synephrine therein, wherein the composition is suitable for oral administration.

Claim 10 (currently amended): A method of alleviating the side effects of a sympathomimetic agent, the method comprising administering *Serenoa repens* or extract thereof, and ~~the~~ a sympathomimetic agent, to a human or animal in need thereof;

Appl. No. 10/044,643
Amdt. dated June 16, 2003
Reply to Office Action of December 17, 2002

wherein the *Serenoa repens* or extract thereof is administered in an amount effective to reduce side effects of the sympathomimetic agent.

Claim 11 (original): The method of claim 10, wherein the *Serenoa repens* or extract thereof has anti-adrenergic activity.

Claim 12 (original): The method of claim 11, wherein the anti-adrenergic activity is inhibition of agonist binding the alpha-adrenergic receptor.

Claim 13 (original): The method of claim 10, wherein the *Serenoa repens* or extract thereof is administered in a pharmaceutically acceptable form.

Claim 14 (previously cancelled)

Claim 15 (original): The method of claim 10, where the sympathomimetic agent comprises ephedrine or an ephedrine related alkaloid.

B1
Claim 16 (original): The method of claim 10, where the sympathomimetic agent comprises a mixture of ephedrine or ephedrine related alkaloid and caffeine.

Claim 17 (original): The method of claim 10, where the sympathomimetic agent is selected from the group consisting of synephrine, pseudoephedrine and phenylpropanolamine.

Claim 18 (currently amended): The method of claim 10, wherein the sympathomimetic agent is ma huang or other natural sources of ephedrine or related alkaloids, or Citrus aurantium or an extract of Citrus aurantium containing synephrine therein or other natural source of synephrine.

Claim 19 (original): The method of claim 10, wherein the ~~Serenoa repens~~ Serenoa repens or extract thereof is administered at least 24 hours prior to administration of the sympathomimetic agent.

Appl. No. 10/044,645
Amdt. dated June 16, 2003
Reply to Office Action of December 17, 2002

Claim 20 (original): The composition of claim 9, wherein the *Serenoa repens* or extract thereof has anti-adrenergic activity.

Claim 21 (original): The composition of claim 20, wherein the anti-adrenergic activity is inhibition of agonist binding the alpha-adrenergic receptor.

Claim 22 (original): The composition of claim 9, wherein the *Serenoa repens* or extract thereof is administered in a pharmaceutically acceptable form.

Claim 23 (new): The method of claim 10 wherein the *Serenoa repens* or extract thereof and the sympathomimetic agent are administered by a route selected from the group consisting of topical, sublingual, transdermal, oral, parenteral and implantation.

31
Claim 24 (new): The method of claim 19 wherein the *Serenoa repens* or extract thereof and the sympathomimetic agent are administered by a route selected from the group consisting of topical, sublingual, transdermal, oral, parenteral and implantation.

Claim 25 (new): A composition comprising *Serenoa repens* or an extract thereof and a sympathomimetic agent, wherein the sympathomimetic agent is synephrine, or *Citrus aurantium* or other natural source of synephrine or extract thereof containing synephrine therein.

Claim 26 (new): The composition of claim 25, wherein the *Serenoa repens* or extract thereof has anti-adrenergic activity.

Claim 27 (new): The composition of claim 26, wherein the anti-adrenergic activity is inhibition of agonist binding to the alpha-adrenergic receptor.

Claim 28 (new): The composition of claim 25, wherein the composition is in pharmaceutically acceptable form.

NO

102(c)
over
mural
(since
doesn't
say
suitable
for
oral
ingest.)

Appl. No. 10/044,645
Amdt. dated June 16, 2003
Reply to Office Action of December 17, 2002

Claim 29 (new): The composition of claim 25, wherein the sympathomimetic agent is
Citrus aurantium.

31
Claim 30 (new): The composition of claim 25, wherein the composition is suitable for
administration by a route selected from the group consisting of topical, sublingual, transdermal,
oral, parenteral and implantation.
